Emcure Pharma shares slip up to 5% post block deals: 2.4% equity changes hands, says report

Earlier, reports said that Bain Capital via BC Asia was likely to sell a 2% stake in the pharma company via block deals. According to reports, the indicative floor price was fixed at ₹1,296.51 per share, a discount of nearly 7% from the last traded price.

The size of the block deal was reported to be worth ₹493 crore.

BC Asia is an affiliate of Bain Capital. It held a 6.3% stake in the company.

Emcure Pharma Q2 FY 26 Results

Emcure Pharmaceuticals reported a 25% increase in profit after tax (PAT) to ₹251 crore in the September quarter (Q2 FY26), aided by strong sales performance across domestic and export markets.

The drug firm posted a profit after tax (PAT) of ₹202 crore during the July-September quarter of the last fiscal.

Revenue from operations rose to ₹2,270 crore in the second quarter as against ₹2,002 crore logged in the year-ago period, Emcure Pharmaceuticals said in a statement.

"We continue to augment our portfolio in all our focus markets through in-licensing and in-house developments. 'The Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry, enabling us to shape the market,' Emcure Pharmaceuticals Chief Executive Officer and Managing Director Satish Mehta said.

The company remains focused on delivering strong growth along with margin improvement in all key businesses, the CEO added.

Novo Nordisk & Emcure partner for weight loss drug in India

Novo Nordisk India and Emcure Pharma early in November 2025 announced a partnership to launch the weight-loss medicine Poviztra, semaglutide injection 2.4 mg, as a second brand of Wegovy in India.

Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025.

It is indicated for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity, as an adjunct to a reduced-calorie diet and increased physical activity, the two companies said in a joint statement.

The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India, it added.

"Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy in India a few months ago.